Assessment of health-related quality of life among adults hospitalized with sickle cell disease vaso-occlusive crisis
- PMID: 31891655
- PMCID: PMC6960476
- DOI: 10.1182/bloodadvances.2019000128
Assessment of health-related quality of life among adults hospitalized with sickle cell disease vaso-occlusive crisis
Abstract
Sickle cell disease (SCD) is characterized by painful vaso-occlusive crises (VOCs). Self-reported pain intensity is often assessed with the Numeric Rating Scale (NRS), whereas newer patient-reported outcome measures (PROMs) assess multidimensional pain in SCD. We describe pain experiences among hospitalized adults with VOCs, using 2 PROMs: the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health and the Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me). Adults with SCD hospitalized with VOCs at 2 academic centers in Boston, Massachusetts, from April 2016 to October 2017 were eligible. Participants completed the NRS and PROMs at admission and 7 days postdischarge. PROM scores were described and compared with population norms. Length of stay (LOS) and 30-day readmission rates were assessed. Forty-two (96%) of 44 eligible patients consented and completed admission assessments. Mean age was 30.2 years (standard deviation, 9.1), 60% were women, 76% were non-Hispanic black, and 64% had hemoglobin SS. Twenty-seven participants (64%) completed postdischarge assessments. Sixty percent had ≥4 VOCs in the last year. Nearly all PROMIS Global Health and ASCQ-Me scores were worse than population norms. NRS and PROMIS Global Physical Health scores improved after discharge, the latter driven principally by improvements in pain. Overall median LOS was 7 days, and 30-day readmission rate was 40.5%. Administration of PROMs among adults with SCD hospitalized for VOCs is feasible and demonstrates participants experienced recurrent, prolonged, and severe VOCs. PROMIS Global and ASCQ-Me scores indicated substantial suffering, and the striking 30-day readmission rate highlights the vulnerability of these patients.
© 2019 by The American Society of Hematology.
Conflict of interest statement
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Figures
References
-
- Brousseau DCA, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77-78. - PubMed
-
- Jackson JL, Lemanek KL, Clough-Paabo E, Rhodes M. Predictors of health-related quality of life over time among adolescents and young adults with sickle cell disease. J Clin Psychol Med Settings. 2014;21(4):313-319. - PubMed
-
- Dampier CD, Smith WR, Wager CG, et al. ; Sickle Cell Disease Clinical Research Network (SCDCRN) . IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials. 2013;10(2):319-331. - PMC - PubMed
-
- Dampier C, LeBeau P, Rhee S, et al. ; Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) Site Investigators . Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86(2):203-205. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
